<DOC>
	<DOCNO>NCT00305799</DOCNO>
	<brief_summary>RATIONALE : Understanding oxaliplatin affect hearing loss , dizziness , peripheral neuropathy may improve ability plan effective treatment patient receive oxaliplatin solid tumor . PURPOSE : This clinical trial study hearing loss dizziness patient receive oxaliplatin solid tumor .</brief_summary>
	<brief_title>Hearing Loss Dizziness Patients Receiving Oxaliplatin Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Define prevalence audiometrically detectable hearing loss patient solid tumor treat oxaliplatin . - Describe association chemotherapy-induced peripheral neuropathy ( CIPN ) audiometrically detectable hearing loss patient . - Describe association CIPN patient self-reported scale include , Peripheral Neuropathy Scale , Hearing Handicap Inventory Adults , Dizziness Handicap Inventory . OUTLINE : This exploratory study . Patients complete three self-reported questionnaire include Peripheral Neuropathy Scale , Hearing Handicap Inventory Adults , Dizziness Handicap Inventory . Patients also ask series question regard symptom complaint hear change , tinnitus , dizziness may experience prior , , completion chemotherapy . Patients also undergo hear test . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis solid tumor Received oxaliplatincontaining chemotherapy regimen within past 15 months* NOTE : *If oxaliplatin omit patient 's recent chemotherapy regimen due ototoxicity , patient still eligible participation study No known CNS metastases PATIENT CHARACTERISTICS : No history spinal injury ECOG performance status 03 No history chronic renal failure No known HIV/AIDS PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>